Skip to content
Dosage GuideResearch Reference

IGF-1 LR3 Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for IGF-1 LR3. All information is for educational purposes only.

Quick Answer

In preclinical research, IGF-1 LR3 is typically administered at dosages ranging from 20–100 mcg per day, often divided into multiple subcutaneous injections. Due to its extended half-life, some protocols administer it once daily or every other day. There are no established human clinical dosages, and its use is investigational only.

→ IGF-1 LR3 Benefits→ IGF-1 LR3 Side Effects→ Full IGF-1 LR3 Profile
Table of Contents

Standard Dosage Range

Research dosing range: 20–100 mcg per day (subcutaneous injection)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Muscle Hypertrophy Research

20–50 mcg1–2× daily
Duration

4–8 weeks

Subcutaneous injection. Often administered post-workout to enhance nutrient uptake into muscle tissue. Cycling recommended due to limited long-term safety data.

Recovery Enhancement Research

20–40 mcg1× daily
Duration

4–6 weeks

Subcutaneous injection. Some researchers use a lower dose to mitigate potential hypoglycemia. Timing may not be critical due to the long half-life.

Anti-Catabolic Research (during caloric restriction)

10–30 mcg1× daily or every other day
Duration

4–8 weeks

Lower dose may be sufficient to preserve muscle mass during periods of reduced caloric intake. Monitor blood glucose closely.

Timing & Frequency

Due to the extended half-life (~20–30 hours), the precise timing of IGF-1 LR3 injections is less critical compared to native IGF-1. Many researchers administer it post-workout or in the morning. Consistent timing is recommended for stable blood levels.

Cycle Guidance

Most preclinical studies use 4–8 week cycles, followed by a break of equal duration. Given the potential for receptor desensitization and limited long-term safety data, cycling is generally advised. Monitor blood glucose and insulin sensitivity throughout the cycle.

Reconstitution Reference

Quick reference for reconstituting IGF-1 LR3. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 1 mg per vial (1000 mcg)
BAC Water Volume1 mL bacteriostatic water for 1000 mcg/mL concentration
Concentration & DrawAt 1000 mcg/mL: 10 mcg = 0.01 mL (1 unit on a 100-unit insulin syringe)
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder refrigerated or frozen.
StabilityReconstituted solution stable up to 7 days refrigerated. Lyophilized powder stable 12–24 months per manufacturer specifications.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard IGF-1 LR3 dosage for muscle growth?
Preclinical research typically uses 20–50 mcg per dose, administered 1–2 times daily via subcutaneous injection. However, there are no established human clinical dosages, and its use is investigational only. Start with the lowest effective dose and monitor for side effects.
How long does IGF-1 LR3 stay in your system?
IGF-1 LR3 has an estimated half-life of 20–30 hours, significantly longer than native IGF-1. This means it takes approximately 5–7 days for the peptide to be mostly cleared from the system after the last injection.
What are the potential side effects of IGF-1 LR3?
Potential side effects include hypoglycemia, increased water retention, joint pain, and potential for increased growth of existing tumors (in preclinical models). These effects have not been systematically studied in humans, and safety data is limited.

Last updated: 2026-02-19